Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Dec. 31, 2015 | Jan. 29, 2016 | |
Document and Entity Information [Abstract] | ||
Entity Registrant Name | APPLIED MICRO CIRCUITS CORP | |
Entity Central Index Key | 711,065 | |
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Dec. 31, 2015 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | Q3 | |
Current Fiscal Year End Date | --03-31 | |
Entity Filer Category | Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 83,537,389 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 | [1] |
Current assets: | |||
Cash and cash equivalents | $ 18,770 | $ 36,495 | |
Short-term investments | 57,673 | 38,863 | |
Accounts receivable, net | 12,452 | 12,407 | |
Inventories | 19,692 | 23,514 | |
Other current assets | 14,578 | 16,840 | |
Total current assets | 123,165 | 128,119 | |
Property and equipment, net | 13,348 | 16,749 | |
Goodwill | 11,425 | 11,425 | |
Other assets | 1,626 | 2,570 | |
Total assets | 149,564 | 158,863 | |
Current liabilities: | |||
Accounts payable | 12,876 | 13,896 | |
Accrued payroll and other accrued liabilities | 4,161 | 3,770 | |
Veloce accrued liability | 6,617 | 5,742 | |
Other accrued liabilities | 8,983 | 7,644 | |
Deferred revenue | 353 | 415 | |
Total current liabilities | 32,990 | 31,467 | |
Non-current liabilities | $ 781 | $ 4,291 | |
Commitments and contingencies (Note 7) | |||
Stockholders’ equity: | |||
Preferred stock, $0.01 par value: Authorized shares - 2,000, none issued and outstanding | $ 0 | $ 0 | |
Common stock, $0.01 par value: Authorized shares - 375,000 at December 31, 2015 and March 31, 2015; Issued and outstanding shares - 83,537 at December 31, 2015 and 80,816 at March 31, 2015 | 835 | 808 | |
Additional paid-in capital | 6,051,474 | 6,032,604 | |
Accumulated other comprehensive loss | (10,031) | (7,486) | |
Accumulated deficit | (5,926,485) | (5,902,821) | |
Total stockholders’ equity | 115,793 | 123,105 | |
Total liabilities and stockholders’ equity | $ 149,564 | $ 158,863 | |
[1] | The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements. |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2015 | Mar. 31, 2015 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (shares) | 2,000,000 | 2,000,000 |
Preferred stock, shares issued (shares) | 0 | 0 |
Preferred stock, shares outstanding (shares) | 0 | 0 |
Common stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (shares) | 375,000,000 | 375,000,000 |
Common stock, shares issued (shares) | 83,537,000 | 80,816,000 |
Common stock, shares outstanding (shares) | 83,537,000 | 80,816,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | ||
Income Statement [Abstract] | |||||
Net revenues | $ 40,623 | $ 36,747 | $ 118,179 | $ 127,964 | |
Cost of revenues | 18,241 | 14,842 | 52,805 | 52,815 | |
Gross profit | 22,382 | 21,905 | 65,374 | 75,149 | |
Operating expenses: | |||||
Research and development | 22,377 | 24,721 | 66,405 | 82,636 | |
Selling, general and administrative | 8,232 | 8,707 | 25,369 | 25,684 | |
Amortization of purchased intangible assets | 0 | 0 | 0 | 105 | |
Restructuring | (29) | 221 | 82 | 1,322 | |
Total operating expenses | 30,580 | 33,649 | 91,856 | 109,747 | |
Operating loss | (8,198) | (11,744) | (26,482) | (34,598) | |
Realized gain on short-term investments and interest income, net | 148 | 485 | 2,024 | 1,214 | |
Other income (expense), net | 21 | (10) | 54 | (2,536) | |
Loss before income taxes | (8,029) | (11,269) | (24,404) | (35,920) | |
Income tax provision (benefit) | 170 | 862 | (740) | 993 | |
Net loss | $ (8,199) | $ (12,131) | $ (23,664) | $ (36,913) | [1] |
Basic and diluted net loss per share (in dollars per share) | $ (0.10) | $ (0.15) | $ (0.29) | $ (0.47) | |
Shares used in calculating basic and diluted net loss per share (in shares) | 83,191 | 78,920 | 82,186 | 78,442 | |
[1] | The Statement of Cash Flows for the nine months ended December 31, 2014 reflects immaterial revisions to correct $0.3 million of outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities and $0.1 million of net realized gains on short-term investments previously classified as net cash used for operating activities to net cash provided by investing activities. As a result, net cash used for operating activities increased by $0.4 million and net cash used for investing activities decreased by the corresponding amount. |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |||
Statement of Comprehensive Income [Abstract] | ||||||
Net loss | $ (8,199) | $ (12,131) | $ (23,664) | $ (36,913) | [1] | |
Other comprehensive loss, net of tax: | ||||||
Unrealized gain (loss) on investments | [2] | (263) | (78) | (2,112) | 218 | |
Loss on foreign currency translation | (63) | (159) | (433) | (374) | ||
Other comprehensive loss, net of tax | (326) | (237) | (2,545) | (156) | ||
Total comprehensive loss | $ (8,525) | $ (12,368) | $ (26,209) | $ (37,069) | ||
[1] | The Statement of Cash Flows for the nine months ended December 31, 2014 reflects immaterial revisions to correct $0.3 million of outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities and $0.1 million of net realized gains on short-term investments previously classified as net cash used for operating activities to net cash provided by investing activities. As a result, net cash used for operating activities increased by $0.4 million and net cash used for investing activities decreased by the corresponding amount. | |||||
[2] | The amounts reclassified from accumulated other comprehensive loss and recorded in net realized gain on short-term investments and interest income, net in the Condensed Consolidated Statement of Operations relating to sale of short-term investments were zero and $1.5 million for the three and nine months ended December 31, 2015, respectively, and $0.1 million each for the three and nine months ended December 31, 2014. Refer to Note 2, Certain Financial Statement Information, to the Condensed Consolidated Financial Statements for additional details. |
Condensed Consolidated Stateme6
Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |
Statement of Comprehensive Income [Abstract] | ||||
Reclassification adjustment from AOCI to earnings, short term investments | $ 0 | $ 100,000 | $ 1,500,000 | $ 100,000 |
Condensed Consolidated Stateme7
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |||
Dec. 31, 2015 | Dec. 31, 2014 | [1] | ||
Adjustments to reconcile net loss to net cash provided by (used for) operating activities: | ||||
Net loss | $ (23,664) | $ (36,913) | ||
Depreciation | 5,699 | 6,598 | ||
Amortization of purchased intangible assets | 0 | 105 | ||
Amortization of bond premium | 429 | 0 | ||
Stock-based compensation expense | 18,167 | 14,303 | ||
Veloce acquisition consideration | 0 | 7,140 | ||
Gain on short-term Investments and other, net | (1,588) | (101) | ||
Non cash restructuring charges | 0 | 14 | ||
Impairment of a strategic investment | 0 | 2,500 | ||
Tax effect on other comprehensive loss | 0 | (34) | ||
Changes in operating assets and liabilities: | ||||
Accounts receivable | (45) | 5,931 | ||
Inventories | 3,849 | (5,271) | ||
Other assets | 2,863 | (736) | ||
Accounts payable | (1,366) | (3,719) | ||
Accrued payroll and other accrued liabilities | 338 | (927) | ||
Veloce accrued liability | (99) | (8,981) | ||
Deferred revenue | (62) | (188) | ||
Net cash provided by (used for) operating activities | 4,521 | (20,279) | ||
Investing activities: | ||||
Proceeds from sales and maturities of short-term investments | 58,227 | 5,198 | ||
Purchases of short-term investments | (78,021) | (2,722) | ||
Proceeds from sale of property and equipment | 31 | 1 | ||
Purchases of property and equipment | (2,039) | (7,291) | ||
Proceeds from sale of TPack | 0 | 3,353 | ||
Net cash used for investing activities | (21,802) | (1,461) | ||
Financing activities: | ||||
Proceeds from issuance of common stock | 1,243 | 1,890 | ||
Funding of restricted stock units withheld for taxes | (1,687) | (1,609) | ||
Net cash provided by (used for) financing activities | (444) | 281 | ||
Net decrease in cash and cash equivalents | (17,725) | (21,459) | ||
Cash and cash equivalents at beginning of year | 36,495 | [2] | 71,539 | |
Cash and cash equivalents at end of period | 18,770 | 50,080 | ||
Supplementary cash flow disclosures: | ||||
Cash paid for income taxes | 519 | 643 | ||
Common stock issued for Veloce merger consideration | $ 2,869 | $ 872 | ||
[1] | The Statement of Cash Flows for the nine months ended December 31, 2014 reflects immaterial revisions to correct $0.3 million of outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities and $0.1 million of net realized gains on short-term investments previously classified as net cash used for operating activities to net cash provided by investing activities. As a result, net cash used for operating activities increased by $0.4 million and net cash used for investing activities decreased by the corresponding amount. | |||
[2] | The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements. |
Condensed Consolidated Stateme8
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) $ in Thousands | 9 Months Ended | |
Dec. 31, 2014USD ($) | ||
Prior Period Adjustments Restatement [Line Items] | ||
Increase(decrease) in outstanding payables related to purchases of property and equipment | $ 7,291 | [1] |
Increase(decrease) in net realized gains on short-term investments | 5,198 | [1] |
Increase in net cash provided by operating activities | (20,279) | [1] |
Decrease in net cash provided by investing activities | 1,461 | [1] |
Previously Reported [Member] | ||
Prior Period Adjustments Restatement [Line Items] | ||
Increase(decrease) in outstanding payables related to purchases of property and equipment | (300) | |
Increase(decrease) in net realized gains on short-term investments | (100) | |
Restatement Adjustment [Member] | ||
Prior Period Adjustments Restatement [Line Items] | ||
Increase(decrease) in outstanding payables related to purchases of property and equipment | 300 | |
Increase(decrease) in net realized gains on short-term investments | 100 | |
Increase in net cash provided by operating activities | 400 | |
Decrease in net cash provided by investing activities | $ 400 | |
[1] | The Statement of Cash Flows for the nine months ended December 31, 2014 reflects immaterial revisions to correct $0.3 million of outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities and $0.1 million of net realized gains on short-term investments previously classified as net cash used for operating activities to net cash provided by investing activities. As a result, net cash used for operating activities increased by $0.4 million and net cash used for investing activities decreased by the corresponding amount. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview Applied Micro Circuits Corporation (the "Company") is a global leader in silicon solutions for next-generation cloud infrastructure and data centers, as well as connectivity products for edge, metro and long-haul communications equipment. Basis of Presentation The Condensed Consolidated Financial Statements include all the accounts of the Company's and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company prepared the accompanying unaudited Condensed Consolidated Financial Statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In management’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to fairly present the Company's financial position, results of operations and cash flows. Interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the Consolidated Financial Statements and notes thereto in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2015. Commencing the quarter ended December 31, 2015, the Company recognizes revenue from development agreements upon completion and acceptance by the customer of contract deliverables or as services are provided, depending on the terms of the arrangement. Revenue is deferred for any amounts billed or received prior to completion of milestones or delivery of services. As the Company retains the intellectual property, or IP, generated from these development agreements, costs related to these arrangements are included in Research and Development ("R&D"), expense. Use of Estimates The preparation of financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to its: • capitalized mask sets including their useful lives, which affect cost of goods sold and property and equipment or R&D expenses, if not capitalized; • inventory valuation, warranty liabilities and revenue reserves, which affect cost of sales, gross margin, and revenues; • allowance for doubtful accounts, which affects operating expenses; • unrealized losses or other-than-temporary impairments of short-term investments available for sale, which affect interest income (expense), net; • valuation of other long-lived assets and goodwill, which affects depreciation and impairment of long-lived assets, impairment of goodwill and apportionment of goodwill related to divestitures; • potential costs of litigation, which affect operating expenses; • valuation of deferred income taxes, which affects income tax expense (benefit); and • stock-based compensation, which affects gross margin and operating expenses. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from management’s estimates. To the extent there are material differences between the estimates and actual results, future results of operations will be affected. Concentrations of Credit Risk and Significant Customers The Company's cash, cash equivalents, short-term investments and accounts receivable are potentially subject to concentration of credit risk. Cash and cash equivalents may be redeemable upon demand and are maintained with several financial institutions that management believes are of high credit quality and therefore bear minimal credit risk. The Company's accounts receivables are derived from revenue earned from customers located around the world. The Company mitigates collection risks from its customers by performing regular credit evaluations of customers' financial condition and payment history and requiring collateral, such as letters of credit, corporate guarantee or prepayment, in certain circumstances. The Company sells its products primarily through direct sales force and distributors. Based on direct shipments, 3 customers individually each accounted for at least 10% of total net revenues during the three months ended December 31, 2015 and 2014 and 2 customers individually each accounted for at least 10% of total net revenues during the nine months ended December 31, 2015 and 2014 . The Company expects that its largest customers collectively will continue to account for a substantial portion of its net revenue for the foreseeable future. New Accounting Pronouncements In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2014-15, "Presentation of Financial Statements - Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern", which requires an entity's management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or within one year after the date that the financial statements are available to be issued, when applicable. The standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating this new standard, and after adoption, it will incorporate this guidance in its assessment of going concern. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers", which will supersede most of the existing revenue recognition guidance under U.S. GAAP. This ASU requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted but adoption on the original effective date is permitted. The ASU allows for either full retrospective or modified retrospective adoption. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures. In November 2015, the FASB issued ASU No. 2015-17, "Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes" to simplify the presentation of deferred taxes in the statement of financial position. The new guidance requires that deferred tax assets and liabilities be classified as non-current in a classified balance sheet. This ASU is effective for fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. Earlier adoption is permitted as of the beginning of an interim or annual reporting period, and may be applied either prospectively, for all deferred tax assets and liabilities, or retrospectively. The Company is currently evaluating the potential effect of this ASU on its financial position. |
Certain Financial Statement Inf
Certain Financial Statement Information | 9 Months Ended |
Dec. 31, 2015 | |
Certain Financial Statement Information [Abstract] | |
CERTAIN FINANCIAL STATEMENT INFORMATION | CERTAIN FINANCIAL STATEMENT INFORMATION Accounts receivable, net: December 31, March 31, (In thousands) Accounts receivable $ 12,732 $ 12,709 Less: allowance for bad debts (280 ) (302 ) $ 12,452 $ 12,407 Inventories: December 31, March 31, (In thousands) Finished goods $ 10,405 $ 15,310 Work in process 6,508 5,377 Raw materials 2,779 2,827 $ 19,692 $ 23,514 Other current assets: December 31, March 31, (In thousands) Prepaid expenses $ 12,284 $ 14,847 Executive deferred compensation assets 985 1,004 Other 1,309 989 $ 14,578 $ 16,840 Property and equipment: Useful Life December 31, March 31, (In years) (In thousands) Machinery and equipment 3-5 $ 38,244 $ 37,286 Leasehold improvements 1-5 7,528 9,909 Computers, office furniture and equipment 3-5 34,444 32,902 80,216 80,097 Less: accumulated depreciation (66,868 ) (63,348 ) $ 13,348 $ 16,749 Other accrued liabilities: December 31, March 31, (In thousands) Employee related liabilities $ 1,377 $ 1,454 Executive deferred compensation 1,017 1,025 Accrued bonus 1,768 39 Income taxes 330 1,311 Other 4,491 3,815 $ 8,983 $ 7,644 Short-term investments: The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument (in thousands): December 31, 2015 March 31, 2015 Amortized Cost Gross Unrealized Estimated Fair Value Amortized Cost Gross Unrealized Estimated Fair Value Gains Losses Gains Losses Cash $ 16,299 $ — $ — $ 16,299 $ 33,936 $ — $ — $ 33,936 Cash equivalents 2,471 — — 2,471 2,559 — — 2,559 U.S. Treasury securities and agency bonds 17,855 — (54 ) 17,801 1,230 — — 1,230 Corporate bonds 25,957 18 (63 ) 25,912 10,772 28 (6 ) 10,794 Asset-backed and mortgage-backed securities 11,948 1 (50 ) 11,899 — 15 — 15 Municipal bonds 2,071 — (10 ) 2,061 — — — — Mutual funds — — — — 24,895 1,955 (59 ) 26,791 Preferred stock — — — — 11 22 — 33 $ 76,601 $ 19 $ (177 ) $ 76,443 $ 73,403 $ 2,020 $ (65 ) $ 75,358 Reported as: Cash and cash equivalents $ 18,770 $ 36,495 Short-term investments available-for-sale 57,673 38,863 $ 76,443 $ 75,358 The established guidelines for measuring fair value and expanded disclosures regarding fair value measurements are defined as a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level 1 — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 — Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 — Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Valuation of instruments includes unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument measured at fair value on a recurring basis (in thousands): December 31, 2015 March 31, 2015 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash $ 16,299 $ — $ — $ 16,299 $ 33,936 $ — $ — $ 33,936 Cash equivalents 2,071 400 — 2,471 2,559 — — 2,559 U.S. Treasury securities and agency bonds 17,801 — — 17,801 1,230 — — 1,230 Corporate bonds — 25,912 — 25,912 — 10,794 — 10,794 Asset-backed and mortgage-backed securities — 11,899 — 11,899 — 15 — 15 Municipal bonds — 2,061 — 2,061 — — — — Mutual funds — — — — 26,791 — — 26,791 Preferred stock — — — — — 33 — 33 $ 36,171 $ 40,272 $ — $ 76,443 $ 64,516 $ 10,842 $ — $ 75,358 There were no significant transfers in and out of Level 1 and Level 2 fair value measurement categories during the three and nine months ended December 31, 2015 and 2014 . The following is a summary of the cost and estimated fair values of available-for-sale securities with stated maturities, which include U.S. Treasury securities and agency bonds, corporate bonds, asset-backed and mortgage-backed securities and municipal bonds, by contractual maturity (in thousands): December 31, 2015 Cost Estimated Fair Value Less than 1 year $ 15,500 $ 15,485 Mature in 1 – 2 years 31,021 30,908 Mature in 3 – 5 years 11,310 11,280 Mature after 5 years — — $ 57,831 $ 57,673 The following is a summary of gross unrealized losses (in thousands): As of December 31, 2015 Less Than 12 Months of Unrealized Losses 12 Months or More of Unrealized Losses Total Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses U.S. Treasury securities and agency bonds $ 17,260 $ (54 ) $ — $ — $ 17,260 $ (54 ) Corporate bonds 18,243 (63 ) — — 18,243 (63 ) Asset-backed and mortgage-backed securities 10,793 (50 ) — — 10,793 (50 ) Municipal bonds 1,898 (10 ) — — 1,898 (10 ) $ 48,194 $ (177 ) $ — $ — $ 48,194 $ (177 ) As of March 31, 2015 Less Than 12 Months of Unrealized Losses 12 Months or More of Unrealized Losses Total Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Corporate bonds $ 878 $ (6 ) $ — $ — $ 878 $ (6 ) Mutual funds 14,592 (17 ) 475 (42 ) 15,067 (59 ) $ 15,470 $ (23 ) $ 475 $ (42 ) $ 15,945 $ (65 ) Realized gain on short-term investments and interest income, net (in thousands): Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Net realized gain (loss) on short-term investments $ (2 ) $ 123 $ 1,557 $ 123 Interest income, net 150 362 467 1,091 $ 148 $ 485 $ 2,024 $ 1,214 Net loss per share: Shares used in basic net loss per share are computed using the weighted average number of common shares outstanding during each period. Shares used in diluted net loss per share include the dilutive effect of common shares potentially issuable upon the exercise of stock options and vesting of restricted stock units ("RSUs"). For the three and nine months ended December 31, 2015 and 2014 , the Company recorded a net loss. As such, all outstanding potential common shares were excluded from the diluted earnings per share computation. The following potentially dilutive common shares are excluded from the computation of net loss per share (in thousands): December 31, December 31, Outstanding stock options 1,650 1,882 Outstanding RSUs 4,752 4,642 ESPP shares 365 350 6,767 6,874 |
Restructuring Charges
Restructuring Charges | 9 Months Ended |
Dec. 31, 2015 | |
Restructuring and Related Activities [Abstract] | |
RESTRUCTURING CHARGES | RESTRUCTURING CHARGES In January 2015, the Company implemented a restructuring plan to reorganize its operations and reduce its workforce and related operating expenses in order to increase its operating efficiencies. This plan eliminated approximately 40 positions, or approximately 7% , of headcount. The Company completed this plan at the end of the quarter ended September 30, 2015 and incurred total restructuring charges of $4.2 million . The following table sets forth a summary of restructuring activities related to the Company's restructuring plan described above (in thousands): Workforce Reduction Operating Lease Commitments Other Total Liability, March 31, 2015 $ 449 $ 113 $ 15 $ 577 Restructuring charges 80 — 2 82 Cash payments (286 ) (61 ) (9 ) (356 ) Non-cash items (22 ) 12 (8 ) (18 ) Liability, December 31, 2015 $ 221 $ 64 $ — $ 285 |
Veloce
Veloce | 9 Months Ended |
Dec. 31, 2015 | |
Business Combinations [Abstract] | |
VELOCE | VELOCE In June 2012, the Company completed its acquisition of Veloce Technologies, Inc. ("Veloce") which had been developing specific ARM-based technology for the Company. The total purchase consideration for Veloce was $178.5 million , the payment of which has been subject to the completion of certain development milestones and vesting requirements. For accounting purposes, the costs incurred in connection with the development milestones relating to Veloce were considered compensatory and recognized as R&D expense in the Condensed Consolidated Statements of Operations. Veloce completed the milestones as of March 31, 2014 and the total consideration of $178.5 million has been recognized as R&D expense as of March 31, 2015. The following table summarizes the cash payment and stock issuance activities during the three and nine months ended December 31, 2015 and 2014 as part of the above arrangement (in thousands): Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Cash payments $ 9 $ 1,482 $ 99 $ 8,981 Value of common stock issued 1 257 2,869 872 Total payments $ 10 $ 1,739 $ 2,968 $ 9,853 Shares of common stock issued — 39 517 116 As of December 31, 2015 , $171.9 million of the total Veloce consideration has been paid and the Company expects that an additional $2.2 million will be paid in cash and stock by March 31, 2016 . The $171.9 million paid to date includes $89.4 million in cash and the issuance of 11.2 million shares of common stock valued at $82.5 million . The consideration not yet paid of $6.6 million can be settled in cash or common stock (or a combination of cash and stock) at the Company's election and is classified as short-term in the Condensed Consolidated Balance Sheet as of December 31, 2015 . |
Stockholders' Equity
Stockholders' Equity | 9 Months Ended |
Dec. 31, 2015 | |
Equity [Abstract] | |
STOCKHOLDERS' EQUITY | STOCKHOLDERS’ EQUITY Stock Options The Company has granted stock options to employees and non-employee directors under several plans. These option plans include two stockholder-approved plans (1992 Equity Incentive Plan and 2011 Equity Incentive Plan) and one plan not approved by stockholders (2000 Equity Incentive Plan). A summary of the Company's stock option activities and related information during the nine months ended December 31, 2015 is as follows: Number of Shares (thousands) Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (millions) Outstanding at the beginning of the year 1,794 $ 9.15 Granted — — Exercised (25 ) $ 5.23 — (1 ) Cancelled (119 ) $ 10.91 Outstanding, vested and exercisable at the end of the period 1,650 $ 9.09 1.2 $ 0.1 (2 ) (1) The aggregate pre-tax intrinsic value is calculated as the difference between the market value on the date of exercise and the exercise price of the shares. (2) The aggregate pre-tax intrinsic value is calculated as the difference between the market value as of December 31, 2015 and the exercise price of the shares. The closing price of the Company’s common stock was $6.37 per share on December 31, 2015 . Restricted Stock Units The Company has granted RSUs to employees and non-employee directors pursuant to its 1992 Equity Incentive Plan and 2011 Equity Incentive Plan. RSUs are share awards that, upon vesting, will deliver to the holder shares of the Company’s common stock. RSUs vest over varying terms, to a maximum of four years from the date of the grant. In May and November 2013, May and October 2014 and November 2015, the Compensation Committee (the "Committee") authorized market-performance based RSUs ("MSUs"). The MSUs will be earned, if at all, based on the Company's Total Shareholder Return (“TSR”) compared to that of the Standard & Poor's Depositary Receipts (the "SPDR") S&P Semiconductor Index ("Index”) over a two -year performance period for half of the MSU award and a three -year performance period for the remaining half of the MSU award. The MSUs will vest between ranges of 0% and 150% or 0% and 175% based on the Company's relative TSR compared to the Index. Total grant-date fair value of these MSUs was $5.5 million , of which $2.6 million expired unvested as of December 31, 2015 . The Company has compensation programs with respect to fiscal 2016 and 2017. The programs include time-based RSUs and financial or operational performance-based awards with payouts that ranges from 0% to 150% of pre-established target levels. Awards under these programs vest in fiscal 2016 through 2018 and can be paid out in common stock or cash. RSU activities during the nine months ended December 31, 2015 is set forth below (in thousands): Number of Shares Outstanding at the beginning of the year 4,328 Awarded 3,406 Vested (2,202 ) Cancelled (780 ) Outstanding at the end of the period 4,752 The weighted average remaining contractual term for the RSUs outstanding as of December 31, 2015 was 1.2 years. As of December 31, 2015 , the aggregate pre-tax intrinsic value of RSUs outstanding was $30.3 million . The aggregate pretax intrinsic value was calculated based on the closing price of the Company’s common stock of $6.37 on December 31, 2015 . The aggregate pre-tax intrinsic value of RSUs vested during the nine months ended December 31, 2015 was $13.9 million . This intrinsic value represents the fair market value of the Company’s common stock on the date of release. Employee Stock Purchase Plan Under the Company's 2012 Employee Stock Purchase Plan, or ESPP, the Company reserved 3.8 million shares for issuance. Under the terms of the ESPP, eligible employees are entitled to purchase common stock, on a semi-annual basis, at a purchase price equal to 85% of the fair market value of the common stock on the first or last day of the offering period, whichever is lower. At December 31, 2015 , 1.6 million shares were available for future issuance under the ESPP. Employees purchased 0.2 million shares at an average price of $4.46 and 0.2 million shares at an average price of $7.09 for the nine months ended December 31, 2015 and 2014 , respectively. The intrinsic value of shares purchased during the nine months ended December 31, 2015 and 2014 was $0.4 million and $0.3 million , respectively. The intrinsic value is calculated as the difference between the market value on the date of purchase and the purchase price of the shares. |
Stock-Based Compensation
Stock-Based Compensation | 9 Months Ended |
Dec. 31, 2015 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION Stock-based compensation cost is measured at the grant date based on the fair value of the award. The fair value of RSUs is estimated using the Company's stock price on the grant date. The fair value of options and employee stock purchase rights is estimated using the Black-Scholes model on the grant date. The Black-Scholes model determines the fair value of share-based payment awards based on assumptions including the Company's stock price on the date of grant, volatility over the term of the awards, actual and projected employee stock option exercise behaviors and risk free interest rate. The MSUs were valued using the Monte Carlo pricing model, which uses the Company's stock price, the Index value, expected volatilities of the Company's stock price and the Index, correlation coefficients and risk free interest rates to determine the fair value. The Company did not grant options during the nine months ended December 31, 2015 and 2014 . The Company did not grant employee stock purchase rights during the three months ended December 31, 2015 . The fair values of the employee stock purchase rights granted during the nine months ended December 31, 2015 and 2014 are estimated as of the grant date using the Black-Scholes option-pricing model with the following assumptions: Nine Months Ended December 31, 2015 2014 Expected life (years) 0.5 0.5 Risk-free interest rate 0.1 % 0.1 % Volatility 57 % 57 % Weighted average fair value $ 1.80 $ 2.57 The weighted average grant-date fair value per share of the RSUs awarded was $6.87 and $5.01 during the three and nine months ended December 31, 2015 , respectively, as compared to $5.82 and $8.20 during the three and nine months ended December 31, 2014 , respectively. The weighted average grant-date fair value per share was calculated based on the fair market value of the Company’s common stock on the respective grant dates. The following tables summarize the allocation of the stock-based compensation expense (in thousands): Stock-based compensation expense by type of grant: Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Stock options and stock purchase rights $ 352 $ 454 $ 848 $ 1,160 RSUs 5,800 4,428 17,347 13,148 6,152 4,882 18,195 14,308 Stock-based compensation capitalized to inventory (11 ) (25 ) (28 ) (5 ) Total $ 6,141 $ 4,857 $ 18,167 $ 14,303 Stock-based compensation expense by cost centers: Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Cost of revenues $ 151 $ 97 $ 377 $ 226 Research and development 4,500 2,992 12,515 9,039 Selling, general and administrative 1,501 1,793 5,303 5,043 6,152 4,882 18,195 14,308 Stock-based compensation capitalized to inventory (11 ) (25 ) (28 ) (5 ) Total $ 6,141 $ 4,857 $ 18,167 $ 14,303 As of December 31, 2015 , the amount of unrecognized stock-based compensation cost, net of estimated forfeitures, related to unvested stock-based awards was $33.4 million which will be recognized over a weighted average period of 1.2 years . |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Dec. 31, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | COMMITMENTS AND CONTINGENCIES Commitments The following table summarizes the Company's contractual operating leases and other purchase commitments as of December 31, 2015 (in thousands): Fiscal Years Ending March 31, Operating Leases Purchase Commitments * Total 2016 (remainder of year) $ 718 $ 22,277 $ 22,995 2017 2,350 10,814 13,164 2018 824 5,225 6,049 2019 472 378 850 Total minimum payments $ 4,364 $ 38,694 $ 43,058 * Includes open purchase orders with terms that generally allow us the option to cancel or reschedule the order, subject to various restrictions and limitations. Also includes the licensing fees relating to the Company's R&D efforts, including IP, technology, product design, test and verification tools, of $15.4 million . Warranty The Company's products typically carry a one -year warranty. The Company establishes reserves for estimated product warranty costs at the time revenue is recognized. Although the Company engages in extensive product quality programs and processes, its warranty obligation is affected by product failure rates, use of materials, and service delivery costs incurred in correcting any product failure. Historically, the Company’s warranty returns have not been material. Intellectual Property Indemnities The Company indemnifies certain customers and contract manufacturers against liability arising from third-party claims of IP rights infringement related to its products. These indemnities appear in development and supply agreements with customers as well as manufacturing service agreements with contract manufacturers and generally survive the expiration of the contract. Given that the amount of any potential liabilities related to such indemnities cannot be determined until an infringement claim has been made, the Company is unable to determine the maximum amount of losses that could be incurred related to such indemnifications. Guarantees and Indemnities In the normal course of business, the Company is occasionally required to provide other guarantees and indemnities for which it may be required to make future payments under specific circumstances. The amount of any potential liabilities related to such obligations cannot be accurately determined until a formal claim is filed. The Company maintains general and product liability insurance which may provide a source of recovery in the event of an indemnification claim. Legal Proceedings The Company is currently a party to certain legal proceedings, including those noted in this section. While the Company presently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm the Company's financial position, results of operations or cash flows, legal proceedings are subject to inherent uncertainties, unfavorable rulings or other events that could occur. In addition, legal proceedings are expensive to prosecute and defend against and can divert management attention and Company resources away from the Company's business objectives. Unfavorable resolutions could include monetary damages against the Company or injunctions or other restrictions on the conduct of the Company’s business, or preclude the Company from recovering the damages it seeks in legal proceedings it has commenced. It is also possible that the Company could conclude it is in the best interests of its stockholders, employees, and customers to settle one or more such matters, and any such settlement could include substantial payments or the surrender of rights to collect payments from third parties. However, the Company has not reached this conclusion with respect to any material matter at this time. In 1993, the Company was named as a Potentially Responsible Party (“PRP”) along with more than 100 other companies that used an Omega Chemical Corporation waste treatment facility in Whittier, California (the “Omega Site”). The U.S. Environmental Protection Agency (“EPA”) has alleged that Omega failed to properly treat and dispose of certain hazardous waste materials at the Omega Site. The Company is a member of a large group of PRPs, known as the Omega Chemical Site PRP Organized Group (“OPOG”), that has agreed to fund certain on-going remediation efforts relating to the Omega Site. Pursuant to a consent decree entered into between EPA and OPOG and approved by the U.S. District Court for the Central District of California (the “Court”), removal of waste materials from the Omega Site has been completed. Efforts to remediate the soil and groundwater at the Omega Site, as well as the extraction of chemical vapors from the soil and improving indoor air quality in and around the site, are still underway and are expected to be ongoing for several more years. In addition, OPOG and EPA are negotiating the remediation plan for a regional groundwater contamination plume allegedly originating at the Omega Site (the Operable Unit 2 or “OU2”). In December 2014, EPA and OPOG agreed upon the basic settlement terms and remediation actions for OU2 that will be set forth in a consent decree that once finalized will be filed with the Court. It is anticipated that Court approval of the consent decree will occur in fiscal year 2017, following which remediation of OU2 will commence. In December 2013, OPOG retained legal counsel to pursue claims against other PRPs for the regional groundwater contamination and, in December 2014, OPOG retained legal counsel to protect its interests in connection with the bankruptcy proceedings filed by an OPOG member. In November 2007, Angeles Chemical Company, located downstream from the Omega Site, filed a lawsuit (the “Angeles Litigation”) in the Court against OPOG and the PRPs for cost recovery and indemnification for future response costs allegedly resulting from OU2. In March 2008, the Court granted OPOG’s motion to stay the Angeles Litigation pending EPA’s determination of how to investigate and remediate the regional groundwater. In January 2012, as a result of challenges made by certain PRPs to the criteria previously used to allocate liability among OPOG members, and of the departure of certain PRPs from OPOG, OPOG approved changes to the cost allocation structure that resulted in an increase to the Company’s proportional allocation of liability. In addition, the subsequent departure or bankruptcy of one or more other PRPs from OPOG could have the effect of increasing the proportional liability of the remaining PRPs, including the Company. To date, the Company has remitted payments to OPOG covering its proportional allocation of liability for legal expenses and remediation costs, and the Company anticipates that its payment obligations relating to the Omega Site will increase once the OU2 consent decree is finalized. Notwithstanding such anticipated increases, the Company does not currently believe its total share of remediation-related expenses will be material to the Company’s financial statements, based on the Company’s approximately 0.5% contribution to the total waste tonnage sent to the site and current estimates of the potential aggregate remediation costs. Based on currently available information, the Company has a loss accrual that is not material and believes that the actual amount of its costs will not be materially different from the amount accrued. However, proceedings are ongoing and the eventual outcome of the clean-up efforts and the pending litigation matters is uncertain at this time. Based on currently available information, the Company does not believe that any eventual outcome will have a material adverse effect on its business or operations. |
Summary of Significant Accoun16
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Dec. 31, 2015 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The Condensed Consolidated Financial Statements include all the accounts of the Company's and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company prepared the accompanying unaudited Condensed Consolidated Financial Statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In management’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to fairly present the Company's financial position, results of operations and cash flows. Interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the Consolidated Financial Statements and notes thereto in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2015. Commencing the quarter ended December 31, 2015, the Company recognizes revenue from development agreements upon completion and acceptance by the customer of contract deliverables or as services are provided, depending on the terms of the arrangement. Revenue is deferred for any amounts billed or received prior to completion of milestones or delivery of services. As the Company retains the intellectual property, or IP, generated from these development agreements, costs related to these arrangements are included in Research and Development ("R&D"), expense. |
Use of Estimates | Use of Estimates The preparation of financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to its: • capitalized mask sets including their useful lives, which affect cost of goods sold and property and equipment or R&D expenses, if not capitalized; • inventory valuation, warranty liabilities and revenue reserves, which affect cost of sales, gross margin, and revenues; • allowance for doubtful accounts, which affects operating expenses; • unrealized losses or other-than-temporary impairments of short-term investments available for sale, which affect interest income (expense), net; • valuation of other long-lived assets and goodwill, which affects depreciation and impairment of long-lived assets, impairment of goodwill and apportionment of goodwill related to divestitures; • potential costs of litigation, which affect operating expenses; • valuation of deferred income taxes, which affects income tax expense (benefit); and • stock-based compensation, which affects gross margin and operating expenses. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from management’s estimates. To the extent there are material differences between the estimates and actual results, future results of operations will be affected. |
Concentrations of Credit Risk and Significant Customers | Concentrations of Credit Risk and Significant Customers The Company's cash, cash equivalents, short-term investments and accounts receivable are potentially subject to concentration of credit risk. Cash and cash equivalents may be redeemable upon demand and are maintained with several financial institutions that management believes are of high credit quality and therefore bear minimal credit risk. The Company's accounts receivables are derived from revenue earned from customers located around the world. The Company mitigates collection risks from its customers by performing regular credit evaluations of customers' financial condition and payment history and requiring collateral, such as letters of credit, corporate guarantee or prepayment, in certain circumstances. The Company sells its products primarily through direct sales force and distributors. Based on direct shipments, 3 customers individually each accounted for at least 10% of total net revenues during the three months ended December 31, 2015 and 2014 and 2 customers individually each accounted for at least 10% of total net revenues during the nine months ended December 31, 2015 and 2014 . The Company expects that its largest customers collectively will continue to account for a substantial portion of its net revenue for the foreseeable future. |
New Accounting Pronouncements | New Accounting Pronouncements In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2014-15, "Presentation of Financial Statements - Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern", which requires an entity's management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or within one year after the date that the financial statements are available to be issued, when applicable. The standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating this new standard, and after adoption, it will incorporate this guidance in its assessment of going concern. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers", which will supersede most of the existing revenue recognition guidance under U.S. GAAP. This ASU requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted but adoption on the original effective date is permitted. The ASU allows for either full retrospective or modified retrospective adoption. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures. In November 2015, the FASB issued ASU No. 2015-17, "Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes" to simplify the presentation of deferred taxes in the statement of financial position. The new guidance requires that deferred tax assets and liabilities be classified as non-current in a classified balance sheet. This ASU is effective for fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. Earlier adoption is permitted as of the beginning of an interim or annual reporting period, and may be applied either prospectively, for all deferred tax assets and liabilities, or retrospectively. The Company is currently evaluating the potential effect of this ASU on its financial position. |
Warrant, Intellectual Property Indemnities, Guarantees and Indemnities | Warranty The Company's products typically carry a one -year warranty. The Company establishes reserves for estimated product warranty costs at the time revenue is recognized. Although the Company engages in extensive product quality programs and processes, its warranty obligation is affected by product failure rates, use of materials, and service delivery costs incurred in correcting any product failure. Historically, the Company’s warranty returns have not been material. Intellectual Property Indemnities The Company indemnifies certain customers and contract manufacturers against liability arising from third-party claims of IP rights infringement related to its products. These indemnities appear in development and supply agreements with customers as well as manufacturing service agreements with contract manufacturers and generally survive the expiration of the contract. Given that the amount of any potential liabilities related to such indemnities cannot be determined until an infringement claim has been made, the Company is unable to determine the maximum amount of losses that could be incurred related to such indemnifications. Guarantees and Indemnities In the normal course of business, the Company is occasionally required to provide other guarantees and indemnities for which it may be required to make future payments under specific circumstances. The amount of any potential liabilities related to such obligations cannot be accurately determined until a formal claim is filed. The Company maintains general and product liability insurance which may provide a source of recovery in the event of an indemnification claim. |
Certain Financial Statement I17
Certain Financial Statement Information (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Certain Financial Statement Information [Abstract] | |
Schedule of Accounts receivable | Accounts receivable, net: December 31, March 31, (In thousands) Accounts receivable $ 12,732 $ 12,709 Less: allowance for bad debts (280 ) (302 ) $ 12,452 $ 12,407 |
Schedule of Inventories | Inventories: December 31, March 31, (In thousands) Finished goods $ 10,405 $ 15,310 Work in process 6,508 5,377 Raw materials 2,779 2,827 $ 19,692 $ 23,514 |
Schedule of Other current assets | Other current assets: December 31, March 31, (In thousands) Prepaid expenses $ 12,284 $ 14,847 Executive deferred compensation assets 985 1,004 Other 1,309 989 $ 14,578 $ 16,840 |
Schedule of Property and equipment | Property and equipment: Useful Life December 31, March 31, (In years) (In thousands) Machinery and equipment 3-5 $ 38,244 $ 37,286 Leasehold improvements 1-5 7,528 9,909 Computers, office furniture and equipment 3-5 34,444 32,902 80,216 80,097 Less: accumulated depreciation (66,868 ) (63,348 ) $ 13,348 $ 16,749 |
Schedule of Other accrued liabilities | Other accrued liabilities: December 31, March 31, (In thousands) Employee related liabilities $ 1,377 $ 1,454 Executive deferred compensation 1,017 1,025 Accrued bonus 1,768 39 Income taxes 330 1,311 Other 4,491 3,815 $ 8,983 $ 7,644 |
Schedule of Cash, cash equivalents and available-for-sale investments by type of instruments | Short-term investments: The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument (in thousands): December 31, 2015 March 31, 2015 Amortized Cost Gross Unrealized Estimated Fair Value Amortized Cost Gross Unrealized Estimated Fair Value Gains Losses Gains Losses Cash $ 16,299 $ — $ — $ 16,299 $ 33,936 $ — $ — $ 33,936 Cash equivalents 2,471 — — 2,471 2,559 — — 2,559 U.S. Treasury securities and agency bonds 17,855 — (54 ) 17,801 1,230 — — 1,230 Corporate bonds 25,957 18 (63 ) 25,912 10,772 28 (6 ) 10,794 Asset-backed and mortgage-backed securities 11,948 1 (50 ) 11,899 — 15 — 15 Municipal bonds 2,071 — (10 ) 2,061 — — — — Mutual funds — — — — 24,895 1,955 (59 ) 26,791 Preferred stock — — — — 11 22 — 33 $ 76,601 $ 19 $ (177 ) $ 76,443 $ 73,403 $ 2,020 $ (65 ) $ 75,358 Reported as: Cash and cash equivalents $ 18,770 $ 36,495 Short-term investments available-for-sale 57,673 38,863 $ 76,443 $ 75,358 |
Schedule of Cash, cash equivalents and available-for-sale investments by type of instruments measured at fair value on recurring basis | The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument measured at fair value on a recurring basis (in thousands): December 31, 2015 March 31, 2015 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash $ 16,299 $ — $ — $ 16,299 $ 33,936 $ — $ — $ 33,936 Cash equivalents 2,071 400 — 2,471 2,559 — — 2,559 U.S. Treasury securities and agency bonds 17,801 — — 17,801 1,230 — — 1,230 Corporate bonds — 25,912 — 25,912 — 10,794 — 10,794 Asset-backed and mortgage-backed securities — 11,899 — 11,899 — 15 — 15 Municipal bonds — 2,061 — 2,061 — — — — Mutual funds — — — — 26,791 — — 26,791 Preferred stock — — — — — 33 — 33 $ 36,171 $ 40,272 $ — $ 76,443 $ 64,516 $ 10,842 $ — $ 75,358 |
Schedule of Cost and estimated fair values of available-for-sale securities with stated maturities by contractual maturity | The following is a summary of the cost and estimated fair values of available-for-sale securities with stated maturities, which include U.S. Treasury securities and agency bonds, corporate bonds, asset-backed and mortgage-backed securities and municipal bonds, by contractual maturity (in thousands): December 31, 2015 Cost Estimated Fair Value Less than 1 year $ 15,500 $ 15,485 Mature in 1 – 2 years 31,021 30,908 Mature in 3 – 5 years 11,310 11,280 Mature after 5 years — — $ 57,831 $ 57,673 |
Schedule of Gross unrealized losses | The following is a summary of gross unrealized losses (in thousands): As of December 31, 2015 Less Than 12 Months of Unrealized Losses 12 Months or More of Unrealized Losses Total Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses U.S. Treasury securities and agency bonds $ 17,260 $ (54 ) $ — $ — $ 17,260 $ (54 ) Corporate bonds 18,243 (63 ) — — 18,243 (63 ) Asset-backed and mortgage-backed securities 10,793 (50 ) — — 10,793 (50 ) Municipal bonds 1,898 (10 ) — — 1,898 (10 ) $ 48,194 $ (177 ) $ — $ — $ 48,194 $ (177 ) As of March 31, 2015 Less Than 12 Months of Unrealized Losses 12 Months or More of Unrealized Losses Total Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Estimated Fair Value Gross Unrealized Losses Corporate bonds $ 878 $ (6 ) $ — $ — $ 878 $ (6 ) Mutual funds 14,592 (17 ) 475 (42 ) 15,067 (59 ) $ 15,470 $ (23 ) $ 475 $ (42 ) $ 15,945 $ (65 ) |
Schedule of Interest income, net | Realized gain on short-term investments and interest income, net (in thousands): Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Net realized gain (loss) on short-term investments $ (2 ) $ 123 $ 1,557 $ 123 Interest income, net 150 362 467 1,091 $ 148 $ 485 $ 2,024 $ 1,214 |
Schedule of potentially dilutive common shares excluded from EPS computation | The following potentially dilutive common shares are excluded from the computation of net loss per share (in thousands): December 31, December 31, Outstanding stock options 1,650 1,882 Outstanding RSUs 4,752 4,642 ESPP shares 365 350 6,767 6,874 |
Restructuring Charges (Tables)
Restructuring Charges (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Restructuring and Related Activities [Abstract] | |
Schedule of restructuring activity | The following table sets forth a summary of restructuring activities related to the Company's restructuring plan described above (in thousands): Workforce Reduction Operating Lease Commitments Other Total Liability, March 31, 2015 $ 449 $ 113 $ 15 $ 577 Restructuring charges 80 — 2 82 Cash payments (286 ) (61 ) (9 ) (356 ) Non-cash items (22 ) 12 (8 ) (18 ) Liability, December 31, 2015 $ 221 $ 64 $ — $ 285 |
Veloce (Tables)
Veloce (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Business Combinations [Abstract] | |
Schedule of cash payments and stock issuance activities | The following table summarizes the cash payment and stock issuance activities during the three and nine months ended December 31, 2015 and 2014 as part of the above arrangement (in thousands): Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Cash payments $ 9 $ 1,482 $ 99 $ 8,981 Value of common stock issued 1 257 2,869 872 Total payments $ 10 $ 1,739 $ 2,968 $ 9,853 Shares of common stock issued — 39 517 116 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Equity [Abstract] | |
Schedule of Option Activity Under Stock Incentive Plans | A summary of the Company's stock option activities and related information during the nine months ended December 31, 2015 is as follows: Number of Shares (thousands) Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (millions) Outstanding at the beginning of the year 1,794 $ 9.15 Granted — — Exercised (25 ) $ 5.23 — (1 ) Cancelled (119 ) $ 10.91 Outstanding, vested and exercisable at the end of the period 1,650 $ 9.09 1.2 $ 0.1 (2 ) (1) The aggregate pre-tax intrinsic value is calculated as the difference between the market value on the date of exercise and the exercise price of the shares. (2) The aggregate pre-tax intrinsic value is calculated as the difference between the market value as of December 31, 2015 and the exercise price of the shares. The closing price of the Company’s common stock was $6.37 per share on December 31, 2015 . |
Schedule of Restricted Stock Unit Activity | RSU activities during the nine months ended December 31, 2015 is set forth below (in thousands): Number of Shares Outstanding at the beginning of the year 4,328 Awarded 3,406 Vested (2,202 ) Cancelled (780 ) Outstanding at the end of the period 4,752 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Schedule of Assumptions Used | The Company did not grant employee stock purchase rights during the three months ended December 31, 2015 . The fair values of the employee stock purchase rights granted during the nine months ended December 31, 2015 and 2014 are estimated as of the grant date using the Black-Scholes option-pricing model with the following assumptions: Nine Months Ended December 31, 2015 2014 Expected life (years) 0.5 0.5 Risk-free interest rate 0.1 % 0.1 % Volatility 57 % 57 % Weighted average fair value $ 1.80 $ 2.57 |
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units | The following tables summarize the allocation of the stock-based compensation expense (in thousands): Stock-based compensation expense by type of grant: Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Stock options and stock purchase rights $ 352 $ 454 $ 848 $ 1,160 RSUs 5,800 4,428 17,347 13,148 6,152 4,882 18,195 14,308 Stock-based compensation capitalized to inventory (11 ) (25 ) (28 ) (5 ) Total $ 6,141 $ 4,857 $ 18,167 $ 14,303 |
Summary of Stock-Based Compensation Expense | Stock-based compensation expense by cost centers: Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Cost of revenues $ 151 $ 97 $ 377 $ 226 Research and development 4,500 2,992 12,515 9,039 Selling, general and administrative 1,501 1,793 5,303 5,043 6,152 4,882 18,195 14,308 Stock-based compensation capitalized to inventory (11 ) (25 ) (28 ) (5 ) Total $ 6,141 $ 4,857 $ 18,167 $ 14,303 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 9 Months Ended |
Dec. 31, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Contractual Obligation by Fiscal Year Maturity | The following table summarizes the Company's contractual operating leases and other purchase commitments as of December 31, 2015 (in thousands): Fiscal Years Ending March 31, Operating Leases Purchase Commitments * Total 2016 (remainder of year) $ 718 $ 22,277 $ 22,995 2017 2,350 10,814 13,164 2018 824 5,225 6,049 2019 472 378 850 Total minimum payments $ 4,364 $ 38,694 $ 43,058 * Includes open purchase orders with terms that generally allow us the option to cancel or reschedule the order, subject to various restrictions and limitations. Also includes the licensing fees relating to the Company's R&D efforts, including IP, technology, product design, test and verification tools, of $15.4 million . |
Certain Financial Statement I23
Certain Financial Statement Information - Accounts Receivable (Details) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 | |
Schedule of Accounts receivable | |||
Accounts receivable | $ 12,732 | $ 12,709 | |
Less: allowance for bad debts | (280) | (302) | |
Accounts receivable, net | $ 12,452 | $ 12,407 | [1] |
[1] | The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements. |
Certain Financial Statement I24
Certain Financial Statement Information - Inventories (Details) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 | |
Schedule of Inventories | |||
Finished goods | $ 10,405 | $ 15,310 | |
Work in process | 6,508 | 5,377 | |
Raw materials | 2,779 | 2,827 | |
Inventories, total | $ 19,692 | $ 23,514 | [1] |
[1] | The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements. |
Certain Financial Statement I25
Certain Financial Statement Information - Other Current Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 | |
Schedule of Other current assets | |||
Prepaid expenses | $ 12,284 | $ 14,847 | |
Executive deferred compensation assets | 985 | 1,004 | |
Other | 1,309 | 989 | |
Other current assets, total | $ 14,578 | $ 16,840 | [1] |
[1] | The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements. |
Certain Financial Statement I26
Certain Financial Statement Information - Property and Equipment (Details) - USD ($) $ in Thousands | 9 Months Ended | ||
Dec. 31, 2015 | Mar. 31, 2015 | ||
Schedule of Property and equipment | |||
Machinery and equipment | $ 38,244 | $ 37,286 | |
Leasehold improvements | 7,528 | 9,909 | |
Computers, office furniture and equipment | 34,444 | 32,902 | |
Property and equipment, gross | 80,216 | 80,097 | |
Less: accumulated depreciation | (66,868) | (63,348) | |
Property and equipment, net | $ 13,348 | $ 16,749 | [1] |
Machinery and Equipment | Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life (in years) | 3 years | ||
Machinery and Equipment | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life (in years) | 5 years | ||
Leasehold Improvements | Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life (in years) | 1 year | ||
Leasehold Improvements | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life (in years) | 5 years | ||
Computers, Office Furniture and Equipment | Minimum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life (in years) | 3 years | ||
Computers, Office Furniture and Equipment | Maximum | |||
Property, Plant and Equipment [Line Items] | |||
Useful life (in years) | 5 years | ||
[1] | The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements. |
Certain Financial Statement I27
Certain Financial Statement Information - Other Accrued Liabiliteis (Details) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 | |
Schedule of other accrued liabilities | |||
Employee related liabilities | $ 1,377 | $ 1,454 | |
Executive deferred compensation | 1,017 | 1,025 | |
Accrued bonus | 1,768 | 39 | |
Income taxes | 330 | 1,311 | |
Other | 4,491 | 3,815 | |
Total other accrued liabilities | $ 8,983 | $ 7,644 | [1] |
[1] | The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements. |
Certain Financial Statement I28
Certain Financial Statement Information - Short-Term Investments (Details) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 | Dec. 31, 2014 | [2] | Mar. 31, 2014 | [2] | |
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments | |||||||
Available-for-sale Securities, Amortized Cost | $ 76,601 | $ 73,403 | |||||
Available-for-sale Securities, Gross Unrealized Gains | 19 | 2,020 | |||||
Available-for-sale Securities, Gross Unrealized Losses | (177) | (65) | |||||
Available-for-sale Securities, Estimated Fair Value | 76,443 | 75,358 | |||||
Cash and cash equivalents | 18,770 | 36,495 | [1] | $ 50,080 | $ 71,539 | ||
Short-term investments available-for-sale | 57,673 | 38,863 | [1] | ||||
Cash, Cash equivalents and Short-term investments, Estimated Fair Value | 76,443 | 75,358 | |||||
Cash | |||||||
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments | |||||||
Cash and Cash equivalents, Estimated Fair Value | 16,299 | 33,936 | |||||
Cash equivalents | |||||||
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments | |||||||
Cash and Cash equivalents, Estimated Fair Value | 2,471 | 2,559 | |||||
U.S Treasury securities and agency bonds | |||||||
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments | |||||||
Available-for-sale Securities, Amortized Cost | 17,855 | 1,230 | |||||
Available-for-sale Securities, Gross Unrealized Gains | 0 | 0 | |||||
Available-for-sale Securities, Gross Unrealized Losses | (54) | 0 | |||||
Available-for-sale Securities, Estimated Fair Value | 17,801 | 1,230 | |||||
Corporate bonds | |||||||
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments | |||||||
Available-for-sale Securities, Amortized Cost | 25,957 | 10,772 | |||||
Available-for-sale Securities, Gross Unrealized Gains | 18 | 28 | |||||
Available-for-sale Securities, Gross Unrealized Losses | (63) | (6) | |||||
Available-for-sale Securities, Estimated Fair Value | 25,912 | 10,794 | |||||
Asset-backed and mortgage-backed securities | |||||||
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments | |||||||
Available-for-sale Securities, Amortized Cost | 11,948 | 0 | |||||
Available-for-sale Securities, Gross Unrealized Gains | 1 | 15 | |||||
Available-for-sale Securities, Gross Unrealized Losses | (50) | 0 | |||||
Available-for-sale Securities, Estimated Fair Value | 11,899 | 15 | |||||
Municipal bonds | |||||||
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments | |||||||
Available-for-sale Securities, Amortized Cost | 2,071 | 0 | |||||
Available-for-sale Securities, Gross Unrealized Gains | 0 | 0 | |||||
Available-for-sale Securities, Gross Unrealized Losses | (10) | 0 | |||||
Available-for-sale Securities, Estimated Fair Value | 2,061 | 0 | |||||
Mutual Funds | |||||||
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments | |||||||
Available-for-sale Securities, Amortized Cost | 0 | 24,895 | |||||
Available-for-sale Securities, Gross Unrealized Gains | 0 | 1,955 | |||||
Available-for-sale Securities, Gross Unrealized Losses | 0 | (59) | |||||
Available-for-sale Securities, Estimated Fair Value | 0 | 26,791 | |||||
Preferred stock | |||||||
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments | |||||||
Available-for-sale Securities, Amortized Cost | 0 | 11 | |||||
Available-for-sale Securities, Gross Unrealized Gains | 0 | 22 | |||||
Available-for-sale Securities, Gross Unrealized Losses | 0 | 0 | |||||
Available-for-sale Securities, Estimated Fair Value | $ 0 | $ 33 | |||||
[1] | The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements. | ||||||
[2] | The Statement of Cash Flows for the nine months ended December 31, 2014 reflects immaterial revisions to correct $0.3 million of outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities and $0.1 million of net realized gains on short-term investments previously classified as net cash used for operating activities to net cash provided by investing activities. As a result, net cash used for operating activities increased by $0.4 million and net cash used for investing activities decreased by the corresponding amount. |
Certain Financial Statement I29
Certain Financial Statement Information - Short Term Investments Fair Value (Details) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 |
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | $ 76,443 | $ 75,358 |
Cash | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash and cash equivalents | 16,299 | 33,936 |
Cash equivalents | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash and cash equivalents | 2,471 | 2,559 |
U.S Treasury securities and agency bonds | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 17,801 | 1,230 |
Corporate bonds | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 25,912 | 10,794 |
Asset-backed and mortgage-backed securities | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 11,899 | 15 |
Municipal bonds | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 2,061 | 0 |
Mutual Funds | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 26,791 |
Preferred stock | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 33 |
Recurring | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash, cash equivalents and available-for-sale investments | 76,443 | 75,358 |
Recurring | Level 1 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash, cash equivalents and available-for-sale investments | 36,171 | 64,516 |
Recurring | Level 2 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash, cash equivalents and available-for-sale investments | 40,272 | 10,842 |
Recurring | Level 3 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash, cash equivalents and available-for-sale investments | 0 | 0 |
Recurring | Cash | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash and cash equivalents | 16,299 | 33,936 |
Recurring | Cash | Level 1 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash and cash equivalents | 16,299 | 33,936 |
Recurring | Cash | Level 2 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash and cash equivalents | 0 | 0 |
Recurring | Cash | Level 3 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash and cash equivalents | 0 | 0 |
Recurring | Cash equivalents | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash and cash equivalents | 2,471 | 2,559 |
Recurring | Cash equivalents | Level 1 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash and cash equivalents | 2,071 | 2,559 |
Recurring | Cash equivalents | Level 2 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash and cash equivalents | 400 | 0 |
Recurring | Cash equivalents | Level 3 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Cash and cash equivalents | 0 | 0 |
Recurring | U.S Treasury securities and agency bonds | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 17,801 | 1,230 |
Recurring | U.S Treasury securities and agency bonds | Level 1 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 17,801 | 1,230 |
Recurring | U.S Treasury securities and agency bonds | Level 2 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | U.S Treasury securities and agency bonds | Level 3 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | Corporate bonds | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 25,912 | 10,794 |
Recurring | Corporate bonds | Level 1 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | Corporate bonds | Level 2 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 25,912 | 10,794 |
Recurring | Corporate bonds | Level 3 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | Asset-backed and mortgage-backed securities | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 11,899 | 15 |
Recurring | Asset-backed and mortgage-backed securities | Level 1 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | Asset-backed and mortgage-backed securities | Level 2 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 11,899 | 15 |
Recurring | Asset-backed and mortgage-backed securities | Level 3 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | Municipal bonds | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 2,061 | 0 |
Recurring | Municipal bonds | Level 1 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | Municipal bonds | Level 2 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 2,061 | 0 |
Recurring | Municipal bonds | Level 3 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | Mutual Funds | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 26,791 |
Recurring | Mutual Funds | Level 1 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 26,791 |
Recurring | Mutual Funds | Level 2 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | Mutual Funds | Level 3 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | Preferred stock | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 33 |
Recurring | Preferred stock | Level 1 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 0 |
Recurring | Preferred stock | Level 2 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | 0 | 33 |
Recurring | Preferred stock | Level 3 | ||
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis | ||
Available-for-sale securities | $ 0 | $ 0 |
Certain Financial Statement I30
Certain Financial Statement Information - Short-Term Investments Schedule of Maturities (Details) $ in Thousands | Dec. 31, 2015USD ($) |
Schedule of cost and estimated fair values of available-for-sale securities with stated maturities by contractual maturity | |
Less than 1 year, Cost | $ 15,500 |
Mature in 1 - 2 years, Cost | 31,021 |
Mature in 3 - 5 years, Cost | 11,310 |
Mature after 5 years, Cost | 0 |
Cost, Total | 57,831 |
Less than 1 year, Fair Value | 15,485 |
Mature in 1 - 2 years, Fair Value | 30,908 |
Mature in 3 - 5 years, Fair Value | 11,280 |
Mature after 5 years, Fair Value | 0 |
Fair Value, Total | $ 57,673 |
Certain Financial Statement I31
Certain Financial Statement Information - Short-Term Investments Gross Unrealized Losses (Details) - USD ($) $ in Thousands | Dec. 31, 2015 | Mar. 31, 2015 |
Schedule of Gross Unrealized Losses | ||
Less Than 12 Months of Unrealized Losses, Estimated Fair Value | $ 48,194 | $ 15,470 |
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses | (177) | (23) |
12 Months or More of Unrealized Losses, Estimated Fair Value | 0 | 475 |
12 Months or More of Unrealized Losses, Gross Unrealized Losses | 0 | (42) |
Total, Estimated Fair Value | 48,194 | 15,945 |
Total Gross Unrealized Losses | (177) | (65) |
U.S. Treasury securities and agency bonds | ||
Schedule of Gross Unrealized Losses | ||
Less Than 12 Months of Unrealized Losses, Estimated Fair Value | 17,260 | |
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses | (54) | |
12 Months or More of Unrealized Losses, Estimated Fair Value | 0 | |
12 Months or More of Unrealized Losses, Gross Unrealized Losses | 0 | |
Total, Estimated Fair Value | 17,260 | |
Total Gross Unrealized Losses | (54) | |
Corporate bonds | ||
Schedule of Gross Unrealized Losses | ||
Less Than 12 Months of Unrealized Losses, Estimated Fair Value | 18,243 | 878 |
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses | (63) | (6) |
12 Months or More of Unrealized Losses, Estimated Fair Value | 0 | 0 |
12 Months or More of Unrealized Losses, Gross Unrealized Losses | 0 | 0 |
Total, Estimated Fair Value | 18,243 | 878 |
Total Gross Unrealized Losses | (63) | (6) |
Asset-backed and mortgage-backed securities | ||
Schedule of Gross Unrealized Losses | ||
Less Than 12 Months of Unrealized Losses, Estimated Fair Value | 10,793 | |
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses | (50) | |
12 Months or More of Unrealized Losses, Estimated Fair Value | 0 | |
12 Months or More of Unrealized Losses, Gross Unrealized Losses | 0 | |
Total, Estimated Fair Value | 10,793 | |
Total Gross Unrealized Losses | (50) | |
Municipal bonds | ||
Schedule of Gross Unrealized Losses | ||
Less Than 12 Months of Unrealized Losses, Estimated Fair Value | 1,898 | |
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses | (10) | |
12 Months or More of Unrealized Losses, Estimated Fair Value | 0 | |
12 Months or More of Unrealized Losses, Gross Unrealized Losses | 0 | |
Total, Estimated Fair Value | 1,898 | |
Total Gross Unrealized Losses | $ (10) | |
Mutual Funds | ||
Schedule of Gross Unrealized Losses | ||
Less Than 12 Months of Unrealized Losses, Estimated Fair Value | 14,592 | |
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses | (17) | |
12 Months or More of Unrealized Losses, Estimated Fair Value | 475 | |
12 Months or More of Unrealized Losses, Gross Unrealized Losses | (42) | |
Total, Estimated Fair Value | 15,067 | |
Total Gross Unrealized Losses | $ (59) |
Certain Financial Statement I32
Certain Financial Statement Information - Realized Gain on Short-Term Investments and Interest Income, Net (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |
Schedule of Interest Income, Net | ||||
Net realized gain (loss) on short-term investments | $ (2) | $ 123 | $ 1,557 | $ 123 |
Interest income, net | 150 | 362 | 467 | 1,091 |
Realized gain on short-term investments and interest income, net | $ 148 | $ 485 | $ 2,024 | $ 1,214 |
Certain Financial Statement I33
Certain Financial Statement Information - Potentially Dilutive Common Shares (Details) - shares shares in Thousands | 9 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Certain Financial Statement Information [Line Items] | ||
Dilutive securities excluded from the net loss per share computation | 6,767 | 6,874 |
Outstanding stock options | ||
Certain Financial Statement Information [Line Items] | ||
Dilutive securities excluded from the net loss per share computation | 1,650 | 1,882 |
Outstanding RSUs | ||
Certain Financial Statement Information [Line Items] | ||
Dilutive securities excluded from the net loss per share computation | 4,752 | 4,642 |
ESPP shares | ||
Certain Financial Statement Information [Line Items] | ||
Dilutive securities excluded from the net loss per share computation | 365 | 350 |
Restructuring Charges - Additio
Restructuring Charges - Additional Information (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Jan. 31, 2015employee | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Dec. 31, 2015USD ($) | |
Restructuring Cost and Reserve [Line Items] | ||||||
Restructuring charges | $ (29) | $ 221 | $ 82 | $ 1,322 | ||
Restructuring Plan | ||||||
Restructuring Cost and Reserve [Line Items] | ||||||
Number of positions eliminated | employee | 40 | |||||
Number of positions expected to be eliminated (percent) | 7.00% | |||||
Restructuring charges | $ 4,200 |
Restructuring Charges - Restruc
Restructuring Charges - Restructuring Activities (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |
Restructuring Reserve [Roll Forward] | ||||
Liability, beginning balance | $ 577 | |||
Restructuring charges | $ (29) | $ 221 | 82 | $ 1,322 |
Cash payments | (356) | |||
Non-cash items | (18) | |||
Liability, ending balance | 285 | 285 | ||
Workforce Reduction [Member] | ||||
Restructuring Reserve [Roll Forward] | ||||
Liability, beginning balance | 449 | |||
Restructuring charges | 80 | |||
Cash payments | (286) | |||
Non-cash items | (22) | |||
Liability, ending balance | 221 | 221 | ||
Operating Lease Commitments [Member] | ||||
Restructuring Reserve [Roll Forward] | ||||
Liability, beginning balance | 113 | |||
Restructuring charges | 0 | |||
Cash payments | (61) | |||
Non-cash items | 12 | |||
Liability, ending balance | 64 | 64 | ||
Other [Member] | ||||
Restructuring Reserve [Roll Forward] | ||||
Liability, beginning balance | 15 | |||
Restructuring charges | 2 | |||
Cash payments | (9) | |||
Non-cash items | (8) | |||
Liability, ending balance | $ 0 | $ 0 |
Veloce - Additional Information
Veloce - Additional Information (Details) - Veloce Technologies Inc - USD ($) shares in Thousands, $ in Thousands | Jun. 20, 2012 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 |
Business Acquisition [Line Items] | ||||||
Total purchase consideration | $ 178,500 | $ 10 | $ 1,739 | $ 2,968 | $ 9,853 | $ 171,900 |
Cash payments | $ 9 | $ 1,482 | $ 99 | $ 8,981 | $ 89,400 | |
Stock issued (in shares) | 0 | 39 | 517 | 116 | 11,200 | |
Cash and stock to be paid in next period | $ 2,200 | $ 2,200 | $ 2,200 | |||
Total equity value transferred | 82,500 | |||||
Consideration payable in cash or equity | $ 6,600 | $ 6,600 | $ 6,600 |
Veloce - Cash Payments and Stoc
Veloce - Cash Payments and Stock Issuances (Details) - Veloce Technologies Inc - USD ($) shares in Thousands, $ in Thousands | Jun. 20, 2012 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 |
Business Acquisition [Line Items] | ||||||
Cash payments | $ 9 | $ 1,482 | $ 99 | $ 8,981 | $ 89,400 | |
Value of common stock issued | 1 | 257 | 2,869 | 872 | ||
Total payments | $ 178,500 | $ 10 | $ 1,739 | $ 2,968 | $ 9,853 | $ 171,900 |
Shares of common stock issued (in shares) | 0 | 39 | 517 | 116 | 11,200 |
Stockholders' Equity - Stock Op
Stockholders' Equity - Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Millions | 9 Months Ended | |
Dec. 31, 2015USD ($)Approved_Plan$ / sharesshares | ||
Equity [Abstract] | ||
Number of stockholder-approved plans | Approved_Plan | 2 | |
Number of plans unapproved by stockholders | Approved_Plan | 1 | |
Schedule of Option Activity Under Stock Incentive Plans | ||
Number of Shares, Outstanding at the beginning of the year (in shares) | shares | 1,794 | |
Number of Shares, Granted (in shares) | shares | 0 | |
Number of Shares, Exercised (in shares) | shares | (25) | |
Number of Shares, Forfeited (in shares) | shares | (119) | |
Number of Shares, Outstanding at the end of the period (in shares) | shares | 1,650 | |
Number of Shares vested and exercisable at end of period (in shares) | shares | 1,650 | |
Schedule of Weighted Average Exercise Price Per Share Under Stock Incentive Plans | ||
Weighted Average Exercise Price Per Share, Outstanding at the beginning of the year (USD per share) | $ 9.15 | |
Weighted Average Exercise Price Per Share, Granted (USD per share) | 0 | |
Weighted Average Exercise Price Per Share, Exercised (USD per share) | 5.23 | |
Weighted Average Exercise Price Per Share, Forfeited (USD per share) | 10.91 | |
Weighted Average Exercise Price Per Share, Outstanding at the end of the period (USD per share) | 9.09 | |
Weighted Average Exercise Price Per Share, vested and exercisable at the end of the period (USD per share) | $ 9.09 | |
Weighted average remaining contractual term for options outstanding at end of period (in years) | 1 year 2 months 24 days | |
Weighted Average Remaining Contractual Life, vested and exercisable at end of period (in years) | 1 year 2 months 24 days | |
Aggregate pretax intrinsic value of options exercised | $ | $ 0 | [1] |
Aggregate intrinsic value of options outstanding at end of period | $ | 0.1 | [2] |
Aggregate intrinsic value of options, vested and exercisable at end of period | $ | $ 0 | [2] |
Common stock, closing price per share (USD per share) | $ 6.37 | |
[1] | The aggregate pre-tax intrinsic value is calculated as the difference between the market value on the date of exercise and the exercise price of the shares. | |
[2] | The aggregate pre-tax intrinsic value is calculated as the difference between the market value as of December 31, 2015 and the exercise price of the shares. The closing price of the Company’s common stock was $6.37 per share on December 31, 2015. |
Stockholders' Equity - Restrict
Stockholders' Equity - Restricted Stock Units (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions | 9 Months Ended | 31 Months Ended |
Dec. 31, 2015 | Nov. 30, 2015 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | ||
Common stock, closing price per share (USD per share) | $ 6.37 | |
Outstanding RSUs | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | ||
Number of Shares, Beginning balance (in shares) | 4,328 | |
Number of Shares, Awarded (in shares) | 3,406 | |
Number of Shares, Vested (in shares) | (2,202) | |
Number of Shares, Cancelled (in shares) | (780) | |
Number of Shares, Ending balance (in shares) | 4,752 | |
Weighted average remaining contractual term for the restricted stock units outstanding (in years) | 1 year 2 months 10 days | |
Aggregate pre-tax intrinsic value of restricted stock units outstanding which includes performance based awards which are subject to milestone attainments | $ 30.3 | |
Aggregate pretax intrinsic value | 13.9 | |
Performance-Based MSU | ||
Class of Stock [Line Items] | ||
Grants in period, fair value | $ 5.5 | |
Value of shares expired unvested in period | $ 2.6 | |
Performance-Based MSU | First Vesting period | ||
Class of Stock [Line Items] | ||
Award performance period | 2 years | |
Performance-Based MSU | First Vesting period | Minimum | ||
Class of Stock [Line Items] | ||
Vesting percentage | 0.00% | |
Performance-Based MSU | First Vesting period | Maximum | ||
Class of Stock [Line Items] | ||
Vesting percentage | 150.00% | |
Performance-Based MSU | Second Vesting Period | ||
Class of Stock [Line Items] | ||
Award performance period | 3 years | |
Performance-Based MSU | Second Vesting Period | Minimum | ||
Class of Stock [Line Items] | ||
Vesting percentage | 0.00% | |
Performance-Based MSU | Second Vesting Period | Maximum | ||
Class of Stock [Line Items] | ||
Vesting percentage | 175.00% | |
1992 Equity Incentive Plan | Outstanding RSUs | Maximum | ||
Class of Stock [Line Items] | ||
Vesting period, in years | 4 years | |
2011 Equity Incentive Plan | Outstanding RSUs | Maximum | ||
Class of Stock [Line Items] | ||
Vesting period, in years | 4 years | |
Compensation Programs | Minimum | ||
Class of Stock [Line Items] | ||
Award pay out percentage | 0.00% | |
Compensation Programs | Maximum | ||
Class of Stock [Line Items] | ||
Award pay out percentage | 150.00% |
Stockholders' Equity - Employee
Stockholders' Equity - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - 2012 Employee Stock Purchase Plan - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 9 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Class of Stock [Line Items] | ||
Common stock reserved for issuance (in shares) | 3.8 | |
Percentage of purchase price of common stock equal to fair market value | 85.00% | |
Shares available for future issuance (in shares) | 1.6 | |
Average purchase price of shares purchased (in dollars per share) | $ 4.46 | $ 7.09 |
Number of shares purchased (in shares) | 0.2 | 0.2 |
Intrinsic value of shares purchased | $ 0.4 | $ 0.3 |
Stock-Based Compensation - Fair
Stock-Based Compensation - Fair Value Assumptions (Details) - Employee Stock Purchase Plan - $ / shares | 9 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected life (years) | 6 months | 6 months |
Risk-free interest rate | 0.10% | 0.10% |
Volatility | 57.00% | 57.00% |
Weighted average fair value (in dollars per share) | $ 1.80 | $ 2.57 |
Stock-Based Compensation - Stoc
Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units | ||||
Stock-based compensation expense | $ 6,152 | $ 4,882 | $ 18,195 | $ 14,308 |
Stock-based compensation capitalized to inventory | (11) | (25) | (28) | (5) |
Total | 6,141 | 4,857 | 18,167 | 14,303 |
Cost of Revenues | ||||
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units | ||||
Stock-based compensation expense | 151 | 97 | 377 | 226 |
Research and Development Expense | ||||
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units | ||||
Stock-based compensation expense | 4,500 | 2,992 | 12,515 | 9,039 |
Selling, General and Administrative | ||||
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units | ||||
Stock-based compensation expense | 1,501 | 1,793 | 5,303 | 5,043 |
Outstanding stock options | ||||
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units | ||||
Stock-based compensation expense | 352 | 454 | 848 | 1,160 |
Outstanding RSUs | ||||
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units | ||||
Stock-based compensation expense | $ 5,800 | $ 4,428 | $ 17,347 | $ 13,148 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||||
Weighted average grant-date fair value per share of the restricted stock units awarded (in dollars per share) | $ 6.87 | $ 5.82 | $ 5.01 | $ 8.20 |
Unearned stock-based compensation | $ 33.4 | $ 33.4 | ||
Weighted-average period over which the unearned stock-based compensation is expected to be recognized, years | 1 year 2 months |
Commitments and Contingencies -
Commitments and Contingencies - Commitments (Details) $ in Thousands | 9 Months Ended | |
Dec. 31, 2015USD ($) | ||
Operating Leases | ||
2016 (remainder of year) | $ 718 | |
2,017 | 2,350 | |
2,018 | 824 | |
2,019 | 472 | |
Total minimum payments | 4,364 | |
Purchase Commitments | ||
2016 (remainder of year) | 22,277 | [1] |
2,017 | 10,814 | [1] |
2,018 | 5,225 | [1] |
2,019 | 378 | [1] |
Total minimum payments | 38,694 | [1] |
Total | ||
2016 (remainder of year) | 22,995 | |
2,017 | 13,164 | |
2,018 | 6,049 | |
2,019 | 850 | |
Total minimum payments | 43,058 | |
Licensing Costs Due | $ 15,400 | |
Length of warranty (in years) | 1 year | |
[1] | Includes open purchase orders with terms that generally allow us the option to cancel or reschedule the order, subject to various restrictions and limitations. Also includes the licensing fees relating to the Company's R&D efforts, including IP, technology, product design, test and verification tools, of $15.4 million. |
Commitments and Contingencies45
Commitments and Contingencies - Contingencies (Details) - Company | 1 Months Ended | 9 Months Ended |
Jan. 31, 2012 | Dec. 31, 2015 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Companies named as Potentially Responsible Parties (more than) | 100 | |
Percent of contribution to the total waste | 0.50% |